Rush University Medical Center-ko ikertzaileekin lankidetzan egindako argitalpenak (20)

2024

  1. Development and external validation of the 'Global Surgical-Site Infection' (GloSSI) predictive model in adult patients undergoing gastrointestinal surgery

    British Journal of Surgery, Vol. 111, Núm. 6

2023

  1. An International Expert Delphi Consensus on Defining Textbook Outcome in Liver Surgery (TOLS)

    Annals of Surgery, Vol. 277, Núm. 5, pp. 821-828

  2. Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-related Quality of Life for Patients with Relapsed/Refractory Multiple Myeloma: Final Data from the Phase 2 ELOQUENT-3 Trial

    HemaSphere, Vol. 7, Núm. 3, pp. E843

2022

  1. Melphalan flufenamide for relapsed/refractory multiple myeloma

    Drugs of today (Barcelona, Spain : 1998), Vol. 58, Núm. 8, pp. 407-423

  2. Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study

    British Journal of Haematology, Vol. 196, Núm. 3, pp. 639-648

2021

  1. Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 39, Núm. 7, pp. 757-767

2020

  1. Melflufen for relapsed and refractory multiple myeloma

    Expert Opinion on Investigational Drugs, Vol. 29, Núm. 10, pp. 1069-1078

2019

  1. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients with Treatment-Resistant Depression: A Randomized Clinical Trial

    JAMA Psychiatry, Vol. 76, Núm. 9, pp. 893-903

  2. Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: An updated analysis of keynote-010 trial

    Annals of Oncology, Vol. 30, Núm. 2, pp. 281-289

2018

  1. Detecting Mild Cognitive Deficits in Parkinson's Disease: Comparison of Neuropsychological Tests

    Movement Disorders, Vol. 33, Núm. 11, pp. 1750-1759

  2. Relationship between the MDS-UPDRS and Quality of Life: A large multicenter study of 3206 patients

    Parkinsonism and Related Disorders, Vol. 52, pp. 83-89

2017

  1. Differences in MDS-UPDRS Scores Based on Hoehn and Yahr Stage and Disease Duration

    Movement Disorders Clinical Practice, Vol. 4, Núm. 4, pp. 536-544

  2. Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update

    The Lancet Neurology, Vol. 16, Núm. 3, pp. 238-250

2016

  1. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial

    The Lancet, Vol. 387, Núm. 10027, pp. 1540-1550

2012

  1. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines

    Movement Disorders, Vol. 27, Núm. 3, pp. 349-356

2011

  1. Defining the critical hurdles in cancer immunotherapy

    Journal of Translational Medicine

  2. MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PD-MCI

    Movement Disorders, Vol. 26, Núm. 10, pp. 1814-1824

2010

  1. Missing pieces in the Parkinson's disease puzzle

    Nature Medicine, Vol. 16, Núm. 6, pp. 653-661

2005

  1. Transcultural comparison of psychogenic movement disorders

    Movement Disorders, Vol. 20, Núm. 10, pp. 1343-1345

2004

  1. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma

    Biology of Blood and Marrow Transplantation, Vol. 10, Núm. 10, pp. 698-708